A team of Vanderbilt researchers has created a new series of drug candidates against a hard-to-target receptor involved in the formation of blood clots. The research, spearheaded by the labs of Jens Meiler, research professor of chemistry, Craig Lindsley, Executive Director of Warren Center for Neuroscience Drug Discovery and professor of pharmacology, and Heidi Hamm, the Aileen M. Lange and Annie Mary Lyle Professor of Cardiovascular Research and professor of pharmacology, was published in ACS Pharmacology and Translational Science in March 2024.
Damian Di Florio, Ph.D., remembers the lightning-bolt moment five years ago when he began thinking differently about the questions scientists ask. He was a summer undergraduate student working in the
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological.